C4 Therapeutics Stock Performance
| CCCC Stock | USD 2.03 0.11 5.14% |
The firm owns a Beta (Systematic Risk) of 1.72, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, C4 Therapeutics will likely underperform. At this point, C4 Therapeutics has a negative expected return of -0.32%. Please make sure to confirm C4 Therapeutics' mean deviation, information ratio, potential upside, as well as the relationship between the standard deviation and total risk alpha , to decide if C4 Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days C4 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (5.14) | Five Day Return (6.45) | Year To Date Return 5.18 | Ten Year Return (92.04) | All Time Return (92.04) |
1 | Full technical analysis of C4 Therapeutics Inc. stock - 2025 AllTime Highs Verified Chart Pattern Trade Signals - newser.com | 10/31/2025 |
2 | Will C4 Therapeutics Inc. stock deliver long term returns - Trade Exit Summary AI Powered BuySell Recommendations - newser.com | 11/20/2025 |
3 | Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha | 11/26/2025 |
4 | TD Cowen Begins Coverage on C4 Therapeutics - MarketBeat | 12/03/2025 |
5 | With 43 percent stake, C4 Therapeutics, Inc. seems to have captured institutional investors interest | 12/30/2025 |
6 | Acquisition by Grogan Donna Roy of 7513 shares of C4 Therapeutics at 1.93 subject to Rule 16b-3 | 01/02/2026 |
7 | C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF13 Degrader and Discovery Strategy Focused on Novel Target... | 01/14/2026 |
8 | Disposition of 10000 shares by Reyno Leonard of C4 Therapeutics at 2.22 subject to Rule 16b-3 | 01/16/2026 |
9 | Analyzing Arcturus Therapeutics and C4 Therapeutics | 01/21/2026 |
10 | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 01/26/2026 |
| Begin Period Cash Flow | 130 M | |
| Total Cashflows From Investing Activities | -51.3 M |
C4 Therapeutics Relative Risk vs. Return Landscape
If you would invest 261.00 in C4 Therapeutics on October 31, 2025 and sell it today you would lose (58.00) from holding C4 Therapeutics or give up 22.22% of portfolio value over 90 days. C4 Therapeutics is currently does not generate positive expected returns and assumes 4.4277% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than CCCC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
C4 Therapeutics Target Price Odds to finish over Current Price
The tendency of CCCC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.03 | 90 days | 2.03 | about 91.37 |
Based on a normal probability distribution, the odds of C4 Therapeutics to move above the current price in 90 days from now is about 91.37 (This C4 Therapeutics probability density function shows the probability of CCCC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.72 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, C4 Therapeutics will likely underperform. Additionally C4 Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. C4 Therapeutics Price Density |
| Price |
Predictive Modules for C4 Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as C4 Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of C4 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
C4 Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. C4 Therapeutics is not an exception. The market had few large corrections towards the C4 Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold C4 Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of C4 Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | 1.72 | |
σ | Overall volatility | 0.22 | |
Ir | Information ratio | -0.05 |
C4 Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of C4 Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for C4 Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| C4 Therapeutics generated a negative expected return over the last 90 days | |
| C4 Therapeutics has high historical volatility and very poor performance | |
| C4 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 35.58 M. Net Loss for the year was (105.32 M) with loss before overhead, payroll, taxes, and interest of (81.66 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (65.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| C4 Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 |
C4 Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CCCC Stock often depends not only on the future outlook of the current and potential C4 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. C4 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 69.4 M | |
| Cash And Short Term Investments | 244.9 M |
C4 Therapeutics Fundamentals Growth
CCCC Stock prices reflect investors' perceptions of the future prospects and financial health of C4 Therapeutics, and C4 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CCCC Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (2.11) % | ||||
| Current Valuation | 70.19 M | ||||
| Shares Outstanding | 96.91 M | ||||
| Price To Book | 1.30 X | ||||
| Price To Sales | 6.89 X | ||||
| Revenue | 35.58 M | ||||
| Gross Profit | (81.66 M) | ||||
| EBITDA | (103.37 M) | ||||
| Net Income | (105.32 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 65.76 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (65.16 M) | ||||
| Earnings Per Share | (1.67) X | ||||
| Market Capitalization | 207.4 M | ||||
| Total Asset | 349.6 M | ||||
| Retained Earnings | (633.7 M) | ||||
| Working Capital | 212.59 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
About C4 Therapeutics Performance
By analyzing C4 Therapeutics' fundamental ratios, stakeholders can gain valuable insights into C4 Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if C4 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if C4 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.35) | (0.36) | |
| Return On Equity | (0.56) | (0.53) |
Things to note about C4 Therapeutics performance evaluation
Checking the ongoing alerts about C4 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for C4 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| C4 Therapeutics generated a negative expected return over the last 90 days | |
| C4 Therapeutics has high historical volatility and very poor performance | |
| C4 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 35.58 M. Net Loss for the year was (105.32 M) with loss before overhead, payroll, taxes, and interest of (81.66 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (65.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| C4 Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 |
- Analyzing C4 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether C4 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining C4 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating C4 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of C4 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of C4 Therapeutics' stock. These opinions can provide insight into C4 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Transaction History View history of all your transactions and understand their impact on performance |